ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M

ProPhase Labs, Inc.

2025-Q1 EPS reported $0.11 vs consensus -$1.84 ▲ beat (+106.0%)

Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.
Net loss widened to $53.4M ($2.61/share) vs $16.8M ($0.98/share) in FY2023; gross loss of $0.2M.
Manufacturing division sold for ~$23M in Jan 2025; employee count reduced from 96 to 28.
Cash and equivalents $0.7M at Dec 31, 2024, down from $1.6M; working capital deficit of $1.5M.
Company plans cash-pay launch of BE-Smart esophageal test; evaluating sale of Nebula Genomics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.